ALDH1A2, also known as Retinaldehyde Dehydrogenase 2 (RALDH2), is a crucial enzyme in the retinoic acid biosynthesis pathway. This gene encodes a member of the aldehyde dehydrogenase family that catalyzes the oxidation of retinaldehyde (retinal) to retinoic acid (RA), the biologically active form of vitamin A. Retinoic acid serves as a critical signaling molecule in embryonic development, tissue patterning, and cellular differentiation, particularly in the developing and mature [central nervous system](/brain-regions/central-nervous-system).
The role of ALDH1A2 in [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders has garnered significant research attention in recent years. The enzyme's function in dopaminergic neuron development, survival, and function makes it a potential therapeutic target for neurodegenerative conditions affecting the [substantia nigra](/brain-regions/substantia-nigra) and basal ganglia circuits.
ALDH1A2, also known as Retinaldehyde Dehydrogenase 2 (RALDH2), is a crucial enzyme in the retinoic acid biosynthesis pathway. This gene encodes a member of the aldehyde dehydrogenase family that catalyzes the oxidation of retinaldehyde (retinal) to retinoic acid (RA), the biologically active form of vitamin A. Retinoic acid serves as a critical signaling molecule in embryonic development, tissue patterning, and cellular differentiation, particularly in the developing and mature [central nervous system](/brain-regions/central-nervous-system).
The role of ALDH1A2 in [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders has garnered significant research attention in recent years. The enzyme's function in dopaminergic neuron development, survival, and function makes it a potential therapeutic target for neurodegenerative conditions affecting the [substantia nigra](/brain-regions/substantia-nigra) and basal ganglia circuits.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ALDH1A2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ALDH1A2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Aldehyde Dehydrogenase 1 Family Member A2</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>RALDH2, RALDH2, ALDH1A2, ALDH-E2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>15q21.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>8854</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000128918</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O00469</td></tr>
<tr><td><strong>OMIM</strong></td><td>603687</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Retinitis Pigmentosa, Neurodegeneration</td></tr>
</table>
</div>
The ALDH1A2 gene spans approximately 34.5 kb on the long arm of chromosome 15 (15q21.2) and consists of 14 exons encoding a 493-amino acid protein. The gene promoter contains multiple regulatory elements including:
Retinaldehyde Dehydrogenase 2 (RALDH2) is a homotetrameric enzyme with each subunit approximately 56 kDa. The protein adopts the characteristic aldehyde dehydrogenase fold:
| Domain | Residues | Function |
|--------|----------|----------|
| N-terminal domain | 1-150 | Tetramerization interface, NAD(P) binding |
| Catalytic domain | 151-400 | Active site, substrate binding |
| C-terminal domain | 401-493 | Structural stabilization |
The active site contains a catalytic cysteine (Cys302) that performs nucleophilic attack on the aldehyde substrate, converting retinal to retinoic acid. The enzyme has high specificity for 9-cis-retinal and all-trans-retinal, the physiological substrates in the retinoic acid biosynthesis pathway.
ALDH1A2/RALDH2 serves as the primary enzyme responsible for the irreversible oxidation of retinaldehyde to retinoic acid in many tissues, particularly during embryonic development and in specific adult tissues including the brain.
Retinoic acid functions as a ligand for nuclear receptor families:
The RAR/RXR heterodimer binds to retinoic acid response elements (RAREs) in the promoter regions of target genes, regulating transcription of genes involved in:
ALDH1A2 is expressed in multiple tissues with distinct patterns:
| Tissue | Expression Level | Functional Significance |
|--------|-----------------|------------------------|
| [Substantia Nigra](/brain-regions/substantia-nigra) | Moderate | Dopaminergic neuron maintenance |
| [Ventral Tegmental Area](/brain-regions/ventral-tegmental-area) | Moderate | Mesolimbic dopamine pathway |
| [Striatum](/brain-regions/striatum) | Low-Moderate | Modulation of dopaminergic signaling |
| [Cortex](/brain-regions/cortex) | Moderate | Cortical development and function |
| [Retina](/brain-regions/retina) | High | Photoreceptor differentiation |
| Liver | High | Systemic retinoic acid production |
| Kidney | Moderate | Local retinoic acid synthesis |
In the adult brain, ALDH1A2 expression is maintained in regions associated with neurogenesis and synaptic plasticity, suggesting ongoing roles in neuronal homeostasis and repair.
During embryonic development, retinoic acid signaling is essential for the specification and differentiation of midbrain dopaminergic neurons:
ALDH1A2 and retinoic acid signaling are implicated in [Parkinson's disease](/diseases/parkinsons-disease) through multiple mechanisms:
| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Dopamine synthesis | RA regulates tyrosine hydroxylase and aromatic L-amino acid decarboxylase | [Escott et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30267348/) |
| Oxidative stress | RA activates antioxidant gene expression | [Wang et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31102713/) |
| Neuroinflammation | RA modulates microglial activation and cytokine production | [Liao et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30690112/) |
| Neuronal survival | RA promotes anti-apoptotic signaling in dopaminergic neurons | [Kim et al., 2020](https://pubmed.ncbi.nlm.nih.gov/33106893/) |
Retinoic acid and ALDH1A2-based therapeutic strategies for PD include:
Current preclinical studies show promise for retinoic acid-based approaches in protecting dopaminergic neurons and improving behavioral outcomes in PD models.
ALDH1A2 dysfunction may contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis:
ALDH1A2 mutations are associated with recessive retinitis pigmentosa, a progressive retinal degeneration characterized by:
Beyond PD and AD, ALDH1A2/retinoic acid dysregulation has been implicated in:
Retinoic acid exerts anti-inflammatory effects in the brain:
| Treatment | Mechanism | Status | Application |
|-----------|-----------|--------|-------------|
| All-trans-retinoic acid (ATRA) | RAR agonist | Preclinical | PD, AD |
| 9-cis-retinoic acid | RAR/RXR agonist | Preclinical | Neuroprotection |
| RAR-selective agonists | Targeted RA signaling | Investigational | Selective targeting |
| RALDH2 activators | Increase endogenous RA | Preclinical | Local delivery |
RA-based therapies may be combined with:
Mice with ALDH1A2 deletion exhibit:
Brain-specific ALDH1A2 knockout mice show:
RALDH2 overexpressing mice demonstrate:
The following diagram shows the key molecular relationships involving ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2) discovered through SciDEX knowledge graph analysis: